Genome-Wide Study to Identify SNPs and CNPs Associated with Radiation Injury

鉴定与辐射损伤相关的 SNP 和 CNP 的全基因组研究

• 批准号: 8071197
• 负责人: Harry Ostrer
• 金额: $ 53.48万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-01 至 2013-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8071197
• 关键词: Adverse effects; Age; Biological Assay; Brachytherapy; Cancer Patient; Candidate Disease Gene; Case-Control Studies; Clinical; Copy Number Polymorphism; DNA; Development; Diagnosis; Erectile dysfunction; Exhibits; Gene Frequency; Gene Proteins; Genes; Genetic; Genome; Genotype; Goals; Haplotypes; Injury; Knowledge; Malignant neoplasm of prostate; Minor; Morbidity - disease rate; Normal tissue morphology; Pathway interactions; Patients; Performance; Phase; Population; Predictive Value; Predisposition; Principal Investigator; Proctitis; Race; Radiation; Radiation Injuries; Radiation Tolerance; Radiation Toxicity; Radiation therapy; Relative Risks; Research; Sampling; Screening procedure; Series; Single Nucleotide Polymorphism; Staging; Subgroup; Uncertainty; Work; base; cost; density; experience; genome wide association study; innovation; nuclease; programs; public health relevance; urinary; validation studies

DESCRIPTION (provided by applicant): A subgroup of prostate cancer patients treated with brachytherapy experience radiation-induced injury manifested as either urinary morbidity, proctitis or erectile dysfunction (ED). Results have been obtained from a series of studies suggestive of a genetic basis for clinical radiosensitivity and it has been hypothesized that many patients who exhibit normal tissue radiation toxicity harbor specific single nucleotide polymorphisms (SNPs) and copy number polymorphisms (CNPs) associated with a susceptibility for the development of adverse effects resulting from a radiation treatment for prostate cancer. However, the research performed to date has been restricted to genotyping only a limited number of SNPs in a small group of candidate genes. In recognition of our inadequate understanding of the pathways involved in the development of radiation-induced urinary morbidity, proctitis and ED, as well as the incomplete knowledge of the spectrum of genes/proteins involved in the development of these forms of radiation toxicity, it is likely that we have failed to identify many of the SNPs and CNPs that are associated with the development of these manifestations of radiation injury. Therefore, we are proposing a new and innovative strategy to achieve this goal in which a genome wide association study will be performed to discover a more complete spectrum of the SNPs and CNPs (and genes) that are associated with clinical radiosensitivity. This will be a case-control study in which each prostate cancer patient that develops either urinary morbidity, proctitis or ED will be matched on age, race, stage, date of diagnosis and dosimetric parameters, with an appropriate control patient who did not develop that form of radiation injury. There will be 200 cases and 200 controls for each form of radiation injury in this study. Half of the subjects will first be screened for SNPs and CNPs using the Affymetrix 6.0 SNP array. The type I error (a) for rejection of the null hypothesis will be set at 0.0001. Therefore, depending on the minor allele frequency, we will be able to identify SNPs and CNPs whose genome relative risks (GRRs) for the development of each form of radiation induced injury is greater than approximately 2.5. Although this is a relatively modest number of subjects for a genome wide association study, therefore enabling identification of SNPs or CNPs only with relatively high GRRs, it is important to note that only SNPs and CNPs with GRRs greater than roughly 2.5 will likely be of useful predictive value in the actual clinical setting considering the dosimetric uncertainties associated with a standard radiotherapy treatment. A second phase validation study will be performed with a separate replication set comprising the other half of the subjects selected for this project using an a of 0.01, which should eliminate virtually all false positives identified in the initial phase. Finally, we will perform comprehensive SNP screening for all subjects of the DNA region surrounding every SNP that proves positively associated with each form of radiation injury in the replication set of subjects in order to genotype all SNPs in a haplotype block. PUBLIC HEALTH RELEVANCE: This project represents the first study to use the powerful results obtained through the HapMap project and the low cost SNP/CNP genotyping that has become possible with the creation of high density SNP/CNP arrays to perform a genome wide association study to identify SNPs or CNPs associated with the development of radiation injury resulting from treatment for prostate cancer. The results of this project should provide a basis for a predictive screening assay to identify prostate cancer patients who are most likely to develop urinary morbidity, proctitis or ED following radiotherapy.

描述（由申请人提供）：接受近距离放射治疗的前列腺癌患者亚组发生放射诱导损伤，表现为泌尿系统疾病、直肠炎或勃起功能障碍（艾德）。从一系列研究中获得的结果提示了临床放射敏感性的遗传基础，并假设许多表现出正常组织放射毒性的患者具有特定的单核苷酸多态性（SNP）和拷贝数多态性（CNP），这些多态性与前列腺癌放射治疗引起的不良反应的易感性相关。然而，迄今为止的研究仅限于对一小群候选基因中有限数量的SNP进行基因分型。认识到我们对辐射诱导的泌尿系统疾病、直肠炎和艾德的发展所涉及的途径的理解不足，以及对这些形式的辐射毒性的发展所涉及的基因/蛋白质谱的知识不完整，我们很可能未能识别出与这些辐射损伤表现的发展相关的许多SNP和CNP。因此，我们提出了一种新的创新策略来实现这一目标，其中将进行全基因组关联研究，以发现与临床放射敏感性相关的SNP和CNP（和基因）的更完整谱。这将是一项病例对照研究，在该研究中，每例发生泌尿系统疾病、直肠炎或艾德的前列腺癌患者将在年龄、种族、分期、诊断日期和剂量测定参数方面与未发生该形式辐射损伤的适当对照患者相匹配。本研究中每种形式的辐射损伤将有200例病例和200例对照。一半的受试者将首先使用Affysse6.0 SNP阵列筛选SNP和CNP。拒绝零假设的I类错误（a）将设定为0.0001。因此，根据次要等位基因频率，我们将能够鉴定其发生每种形式的辐射诱导损伤的基因组相对风险（GRR）大于约2.5的SNP和CNP。尽管这是用于全基因组关联研究的相对适度数量的受试者，因此能够鉴定仅具有相对高GRR的SNP或CNP，但重要的是要注意，考虑到与标准放射治疗相关的剂量测定不确定性，只有GRR大于约2.5的SNP和CNP可能在实际临床环境中具有有用的预测值。第二阶段验证研究将使用单独的重复集进行，该重复集包括本项目选择的另一半受试者，a为0.01，这应消除初始阶段识别的几乎所有假阳性。最后，我们将对所有受试者进行全面的SNP筛查，以确定单倍型块中所有SNP的基因型，这些SNP被证明与受试者复制组中每种形式的辐射损伤正相关。 公共卫生相关性：该项目代表了第一项使用通过HapMap项目获得的强大结果和低成本SNP/CNP基因分型的研究，该基因分型随着高密度SNP/CNP阵列的创建而成为可能，以进行全基因组关联研究，以识别与前列腺癌治疗引起的辐射损伤相关的SNP或CNP。该项目的结果应提供一个预测性筛查分析的基础，以确定前列腺癌患者谁是最有可能发展泌尿系统疾病，直肠炎或艾德放疗后。